daily-independent logo
Log in
MEDICAL

FDA approves immunotherapy regimen studied by Mayo Clinic

The Food and Drug Administration has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery.

The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.

The approval is based on results from the ATOMIC clinical trial led by Mayo Clinic, according to a press release.

You must be a member to read this story.

Join our family of readers starting at $5 for your first month and support local, unbiased journalism.

Already have an account? Log in to continue.

Otherwise, follow the link below to join.

Please log in to continue

Log in

Other items that may interest you

Hobbs loosens fuel rules for farmers, ranchers

Her son has serious disabilities. She believes she's the best person to teach him

East Valley district's financial report shows mounting budget pressures, rising maintenance costs

Another teen reported missing in Queen Creek

Most popular stories in Daily Independent

Latest winners of Powerball drawings sold at East, West Valley stores

Tempe council to vote on potential license plate reader ban

Fans, experts look for blame in Marvin Harrison Jr.’s now-concluded Cardinals tenure

Shots fired at Scottsdale short-term rental